ReP USP - Resultado da busca

Artigo de periodico
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period (2022)
Boccara, Franck; Caramelli, Bruno ; Calmy, Alexandra; Kumar, Princy; Lopez, J. Antonio G.; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S.
Source: Aids. Unidade: FM
Subjects: TERAPIA ANTIRRETROVIRAL DE ALTA ATIVIDADE, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. Aids, v. 36, n. 5, p. 675-682, 2022Tradução . . Disponível em: https://doi.org/10.1097/QAD.0000000000003175. Acesso em: 16 nov. 2024.
APA
Boccara, F., Caramelli, B., Calmy, A., Kumar, P., Lopez, J. A. G., Bray, S., et al. (2022). Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. Aids, 36( 5), 675-682. doi:10.1097/QAD.0000000000003175
NLM
Boccara F, Caramelli B, Calmy A, Kumar P, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period [Internet]. Aids. 2022 ; 36( 5): 675-682.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/QAD.0000000000003175
Vancouver
Boccara F, Caramelli B, Calmy A, Kumar P, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period [Internet]. Aids. 2022 ; 36( 5): 675-682.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1097/QAD.0000000000003175
Artigo de periodico
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics (2020)
Boccara, Franck; Kumar, Princy; Caramelli, Bruno ; Calmy, Alexandra; Lopez, J. Antonio G; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S
Source: American heart journal. Unidade: FM
Subjects: ANTICORPOS MONOCLONAIS, INFECÇÕES POR HIV, HIPERCOLESTEROLEMIA, DISLIPIDEMIAS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, ESTATINAS, ENZIMAS PROTEOLÍTICAS, ESTUDOS MULTICÊNTRICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, v. 220, p. 203-212, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2019.11.004. Acesso em: 16 nov. 2024.
APA
Boccara, F., Kumar, P., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. American heart journal, 220, 203-212. doi:10.1016/j.ahj.2019.11.004
NLM
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004
Vancouver
Boccara F, Kumar P, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics [Internet]. American heart journal. 2020 ; 220 203-212.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.ahj.2019.11.004
Artigo de periodico
Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study (2020)
Boccara, Franck; Kumar, Princy N; Caramelli, Bruno ; Calmy, Alexandra; Lopez, J. Antonio G; Bray, Sarah; Cyrille, Marcoli; Rosenson, Robert S
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ESTATINAS, COLESTEROL, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS, DISLIPIDEMIAS, HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOCCARA, Franck et al. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, v. 75, n. 20, p. 2570-2584, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2020.03.025. Acesso em: 16 nov. 2024.
APA
Boccara, F., Kumar, P. N., Caramelli, B., Calmy, A., Lopez, J. A. G., Bray, S., et al. (2020). Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study. Journal of the american college of cardiology, 75( 20), 2570-2584. doi:10.1016/j.jacc.2020.03.025
NLM
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025
Vancouver
Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, Cyrille M, Rosenson RS. Evolocumab in HIV-Infected Patients With Dyslipidemia Primary Results of the Randomized, Double-Blind BEIJERINCK Study [Internet]. Journal of the american college of cardiology. 2020 ; 75( 20): 2570-2584.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.jacc.2020.03.025

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies